Butyrolactone I

Research use only, not for human use.

Butyrolactone I is an ATP-competitive inhibitor of CDK and cdc2 kinase family.

Butyrolactone I is an ATP-competitive inhibitor of CDK and cdc2 kinase family. Butyrolactone I shows antitumor effects in non-small cell lung, small cell lung, and prostate cancer cell lines.(In Vitro):Butyrolactone I (70 and 100 μM) increases the percentage of DU145 cells in the 4C phase of the cell cycle. Butyrolactone I increases the amount of cyclin B1 positive cells in the 4C phase on day 1 and returns to normal by day 3. Butyrolactone I inhibits Cdc2 of unsynchronized cultured prostate cancer cells and interrupts the cell cycle progression toward cell division. The Butyrolactone I inhibition of Cdc2 led to the accumulation of cells in the 4C phase without mitosis resulting in an accumulation of cyclin B1.

——

——

Olomoucin

Angiogenesis

CDK

Parasite

——

——

87414-49-1

424.44

C24H24O7

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (235.60 mM)

C([C@]1(C(OC)=O)C(=C(O)C(=O)O1)C2=CC=C(O)C=C2)C3=CC(CC=C(C)C)=C(O)C=C3

——

(-20℃)

With Ice Pack

≥ 2 years